Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

Abstract Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are important for treating patients with preserved left ventricular (LV) ejection fraction (LVEF). Several studies have assessed the effects of SGLT2 inhibitors on LV diastolic function, with conflicting results. In this sub-anal...

Full description

Saved in:
Bibliographic Details
Main Authors: Hiroki Teragawa, Atsushi Tanaka, Kanae Takahashi, Chikage Oshita, Yuko Uchimura, Nozomu Kamei, Hiroyuki Hirai, Michio Shimabukuro, Isao Taguchi, Yosuke Okada, Koichi Node
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Cardiovascular Diabetology
Subjects:
Chronic kidney disease
Echocardiography
Ipragliflozin
Left ventricular diastolic function
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s12933-025-02745-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-025-02745-1

Similar Items